Major Depressive Disorder (MDD) affects approximately 280 million people globally, with current treatments showing significant limitations, including delayed onset of action, low remission rates, and troublesome side effects. Esmethadone (REL-1017, d-methadone) has emerged as a promising agent for MDD. This review examines esmethadone (REL-1017), a novel glutamatergic modulator functioning...
CureusJuly 1, 2024Oluwatosin O Arubuolawe, Ibrahim L Folorunsho, Adeniyi K Busari et al.2 citations
Treatment-resistant depression (TRD) is a significant challenge in psychiatric practice, affecting a substantial proportion of patients with major depressive disorder (MDD). Traditional treatment modalities often fall short, necessitating the exploration of alternative therapies. This literature review examines the combined use of Transcranial Magnetic Stimulation (TMS) and ketamine in treating...